GV150013

CAS No. 167355-22-8

GV150013( —— )

Catalog No. M34275 CAS No. 167355-22-8

GV150013 is an antagonist of cholecystokinin-2 (CCK2) receptor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 299 Get Quote
5MG 455 Get Quote
10MG 620 Get Quote
25MG 911 Get Quote
50MG 1224 Get Quote
100MG 1575 Get Quote
200MG 2133 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    GV150013
  • Note
    Research use only, not for human use.
  • Brief Description
    GV150013 is an antagonist of cholecystokinin-2 (CCK2) receptor.
  • Description
    GV-150013 is a selective CCK-B receptor antagonist. GV-150013 has sleep aid effect.
  • In Vitro
    ——
  • In Vivo
    Animal Model:Old rats .Dosage:0.5 μg/kg, 5μg/kg, 60μg/kg Administration:Intraperitoneal injection, Once Result:The duration of REM sleep and non-REM sleep was longer than that of control.
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Cholecystokinin Receptor
  • Recptor
    cholecystokinin
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    167355-22-8
  • Formula Weight
    534.65
  • Molecular Formula
    C33H34N4O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(C12CC3CC(C1)CC(C2)C3)N4C=5C(N(C(=O)[C@H](NC(NC6=CC=CC=C6)=O)C4=O)C7=CC=CC=C7)=CC=CC5
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Crespi F. Cholecystokinin-B (CCK-B) receptor antagonists improve "aged" sleep: a new class of sleep modulators? Methods Find Exp Clin Pharmacol. 1999 Jan-Feb;21(1):31-8.?
molnova catalog
related products
  • WAY-620645

    WAY-620645 is a CCK antagonist with antitumor and analgesic activities.

  • A-65186

    A-65186 is an A-type glutamatergic cholecystokinin (CCK) antagonist used to study inflammation and gastrointestinal tract injury.

  • Spiroglumide

    Spiroglumide, a CCKB-gastrin antagonist that inhibits dose-dependent pentagastrin-induced acid hypersecretion with an ID50 of 20.1 (8.67-46.4) mg / kg, could be used to explore the physiological role of gastrin in the regulation of human gastric acid secretion.